Skip to main content
. 2016 Jun 3;16:352. doi: 10.1186/s12885-016-2385-z

Fig. 2.

Fig. 2

Schematic of MM-302, a novel HER2-targeted antibody–liposomal doxorubicin conjugate. MM-302 consists of doxorubicin encapsulated by a liposome that is conjugated to an anti-HER2 scFv antibody via a polyethylene glycol spacer (PEG-DSPE). MM-302 thus directly targets PEGylated liposomal doxorubicin to HER2-overexpressing tumor cells